Published in J Am Coll Cardiol on September 12, 2006
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. BMJ (2014) 2.21
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther (2009) 1.73
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Clinical importance of aspirin and clopidogrel resistance. World J Cardiol (2010) 0.95
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance. Cardiovasc Diagn Ther (2013) 0.91
Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options. Vasc Health Risk Manag (2012) 0.88
Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coron Artery Dis (2009) 0.86
A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost (2009) 0.85
Cangrelor increases the magnitude of platelet inhibition and reduces interindividual variability in clopidogrel-pretreated subjects. Neth Heart J (2009) 0.82
Antithrombotic treatment before and after peripheral artery percutaneous angioplasty. Blood Transfus (2009) 0.81
Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. Neth Heart J (2007) 0.81
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost (2013) 0.81
Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry. Am Heart J (2011) 0.81
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.81
Hostility and platelet reactivity in individuals without a history of cardiovascular disease events. Psychosom Med (2009) 0.80
P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use. Ther Adv Chronic Dis (2015) 0.80
Development and validation of an HPLC-MS/MS method to determine clopidogrel in human plasma. Acta Pharm Sin B (2015) 0.80
Evolving role of platelet function testing in coronary artery interventions. Vasc Health Risk Manag (2012) 0.79
The prognostic impact of high on-treatment platelet reactivity with aspirin or ADP receptor antagonists: systematic review and meta-analysis. Biomed Res Int (2014) 0.78
Antiplatelet Resistance-Does it Exist and How to Measure it? Clin Med Cardiol (2009) 0.78
High-maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. PLoS One (2013) 0.77
Effects of 600 mg versus 300 mg loading dose of clopidogrel in Asian patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: long-term follow-up study. Yonsei Med J (2012) 0.77
An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention. Crit Pathw Cardiol (2010) 0.76
P2Y12 Inhibitor Pre-Treatment in Non-ST-Elevation Acute Coronary Syndrome: A Decision-Analytic Model. J Clin Med (2016) 0.75
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.75
The Potential Value of Near Patient Platelet Function Testing in PCI: Randomised Comparison of 600 mg versus 900 mg Clopidogrel Loading Doses. Thrombosis (2009) 0.75
Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention. Vasc Health Risk Manag (2009) 0.75
Oral antiplatelet therapy for acute and chronic management of NSTE ACS: residual ischemic risk and opportunities for improvement. Cardiovasc Drugs Ther (2009) 0.75
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update. Vasc Health Risk Manag (2010) 0.75
Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography. Saudi Med J (2016) 0.75
Association between peak neutrophil count, clopidogrel loading dose, and left ventricular systolic function in patients with primary percutaneous coronary intervention. Mediators Inflamm (2014) 0.75
Morphine Does Not Affect Myocardial Salvage in ST-Segment Elevation Myocardial Infarction. PLoS One (2017) 0.75
Balancing potency of platelet inhibition with bleeding risk in the early treatment of acute coronary syndrome. West J Emerg Med (2009) 0.75
Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med (2008) 3.66
Effects of bariatric surgery on cardiac ectopic fat: lesser decrease in epicardial fat compared to visceral fat loss and no change in myocardial triglyceride content. J Am Coll Cardiol (2012) 2.88
The systemic capillary leak syndrome: a case series of 28 patients from a European registry. Ann Intern Med (2011) 2.88
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). JACC Cardiovasc Interv (2013) 2.65
Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood (2009) 2.64
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost (2007) 2.32
Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet (2011) 1.91
Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring) (2009) 1.77
Modulation of adipose tissue development by pharmacological inhibition of PAI-1. Arterioscler Thromb Vasc Biol (2006) 1.76
Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum (2013) 1.73
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol (2008) 1.71
High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol (2006) 1.68
Description of Mycobacterium conceptionense sp. nov., a Mycobacterium fortuitum group organism isolated from a posttraumatic osteitis inflammation. J Clin Microbiol (2006) 1.64
Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood (2009) 1.62
Tiplaxtinin impairs nutritionally induced obesity in mice. Thromb Haemost (2006) 1.55
Etiologic diagnosis of 204 pericardial effusions. Medicine (Baltimore) (2003) 1.55
Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clin Chim Acta (2010) 1.52
Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. Arterioscler Thromb Vasc Biol (2014) 1.45
Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost (2005) 1.44
Genetics of venous thrombosis: insights from a new genome wide association study. PLoS One (2011) 1.43
Non-invasive diagnostic of cardiac allograft vasculopathy by 31P magnetic resonance chemical shift imaging. Eur J Cardiothorac Surg (2005) 1.41
Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol (2007) 1.36
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) (2009) 1.36
ANKRD26-related thrombocytopenia and myeloid malignancies. Blood (2013) 1.32
Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv (2008) 1.27
Circulating endothelial cell count as a diagnostic marker for non-ST-elevation acute coronary syndromes. Circulation (2004) 1.26
Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. Blood (2012) 1.26
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol (2009) 1.23
The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. J Biol Chem (2002) 1.23
Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab (2002) 1.21
Characterization of human mesenchymal stem cell secretome at early steps of adipocyte and osteoblast differentiation. BMC Mol Biol (2008) 1.17
The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: possible contribution to elevated plasma levels of soluble TNF alpha receptors. Atherosclerosis (2005) 1.16
Platelet-endothelial cell interactions in cerebral malaria: the end of a cordial understanding. Thromb Haemost (2009) 1.16
Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. Br J Haematol (2012) 1.16
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol (2012) 1.14
Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. FASEB J (2009) 1.14
Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation (2012) 1.13
Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum (2006) 1.13
Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler Thromb Vasc Biol (2002) 1.10
Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. Blood (2006) 1.07
Genetic associations for activated partial thromboplastin time and prothrombin time, their gene expression profiles, and risk of coronary artery disease. Am J Hum Genet (2012) 1.05
Management of isolated spontaneous dissection of superior mesenteric artery. Langenbecks Arch Surg (2009) 1.05
Microparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol (2007) 1.03
Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. BMC Med Genet (2011) 1.02
Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol (2007) 1.01
Aspirin noncompliance is the major cause of "aspirin resistance" in patients undergoing coronary stenting. Am Heart J (2009) 1.00
Secretory type II phospholipase A2 is produced and secreted by epicardial adipose tissue and overexpressed in patients with coronary artery disease. J Clin Endocrinol Metab (2009) 0.99
KNG1 Ile581Thr and susceptibility to venous thrombosis. Blood (2011) 0.98
First isolation of Bacteroides thetaiotaomicron from a patient with a cholesteatoma and experiencing meningitis. J Clin Microbiol (2005) 0.98
An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microb Pathog (2011) 0.98
A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. Am J Hum Genet (2010) 0.98
Spectrum of the mutations in Bernard-Soulier syndrome. Hum Mutat (2014) 0.97
miR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS One (2012) 0.97
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol (2007) 0.97
High prevalence of laminopathies among patients with metabolic syndrome. Hum Mol Genet (2011) 0.97
Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) (2012) 0.96
Transcatheter closure of traumatic ventricular septal defect: an alternative to surgical repair? Ann Thorac Surg (2002) 0.96
Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost (2007) 0.95
A novel leukocyte adhesion deficiency III variant: kindlin-3 deficiency results in integrin- and nonintegrin-related defects in different steps of leukocyte adhesion. J Immunol (2011) 0.95
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention (2009) 0.95
European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis (2012) 0.95
HDLs activate ADAM17-dependent shedding. J Cell Physiol (2008) 0.94
Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res (2007) 0.94